Cargando…
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N = 2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin pl...
Autores principales: | Clements, Karen M., Peltz, Gerson, Faries, Douglas E., Lang, Kathleen, Nyambose, Joshua, Earle, Craig C., Sugarman, Katherine P., Taylor, Douglas C. A., Thompson, David, Marciniak, Martin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265238/ https://www.ncbi.nlm.nih.gov/pubmed/22482053 http://dx.doi.org/10.1155/2010/524629 |
Ejemplares similares
-
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
por: Boni, C, et al.
Publicado: (2012) -
Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIIb and IV
por: Umihanic, Sefika, et al.
Publicado: (2014) -
Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023) -
On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970) -
The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
por: Wang, Yuan, et al.
Publicado: (2017)